GLAXOSMITHKLINE
1
GlaxoSmithKline Ltd strengths
Names:
Institution:
GLAXOSMITHKLINE
2
GlaxoSmithKline Ltd strengths
GlaxoSmithKline (GSK) has been in operation for the past sixteen years. During that
period, the company has been experiencing continuous growth particularly due to the
increased combined clientele, capital, and workforce that accompanied the merger that saw
the creation of the company. As with many other mergers in the twenty-first century,
GlaxoSmithKline has managed to accomplish most of its strategies which the individual
companies could not have managed despite the flourishing demand for their products
(Rashmi, 2017). Notably, the two companies had been experiencing challenges related to
competition before the decision for a merger arose. Surprisingly, they were rivals in the
pharmaceutical and health products industry, and this detrimentally affected their operations.
Moreover, Holzweber, Holzweber, Lawson & Addison (N.D) note that competition has been
attributed to the highest percentage of the collapse of companies due to its negative effect on
pricing as each company strives to hold or expand its customer base and supersede the rival.
However, the company has been doing well with a number of strengths being achieved and
which have enabled GSK to expand its operations to more than a hundred countries. The
following section will discuss a number of the strengths that the company holds and
particularly above its rivals.
A variety of quality and rare products
The company has managed to establish a state-of-the-art laboratory through its
extensive research and design (R & D) program whereby it commits huge investments.
However, these investments have necessitated the company to increase its technology of
manufacture and also the value of the products. GSK has also managed to increase its
products to incorporate a wide variety unlike most of its competitors. Interestingly, most of
this company’s drugs are antiviral therapies, nervous system, vaccines, and respiratory
GLAXOSMITHKLINE
3
system. Few companies manufacture drugs of the nervous system, which means that this
company always has the upper hand when it comes to competition and sales. Additionally,
other fields such as vaccines are essential, which means that their demand mainly remains
constant. Notably, GSK recently announced its commitment towards R&D by setting aside of
more than $ 97 million whose aim was to improve its drugs and venture into areas where little
success exists (GlaxoSmithKline, 2015). In R&D alone, the company had more than 13, 000
employees and researchers as at 2013 (Karus, 2015). One such venture is the HIV/AIDS
which, if it succeeds, will make the company among the most successful in medical
discoveries. Most of its success has arisen from its adoption of advanced technology. Notably,
it goes a notch higher to seek a partnership with renowned tech firms such as McLaren
Technology Group to facilitate its conquest.
Vast resources that facilitate its operations
As at 2015, the company was already operating in more than 115 countries globally.
The company has grown to be one of the most successful in its field whereby it currently
ranks at number six globally. Interestingly, its high growth rate indicates that it might soon be
surpassing some of the leaders in the pharmaceutical industry. With more than 96,000
employees, and with more than 13,000 being in the R&D sector alone, the company is able to
research and manufacture a large variety of drugs which reach millions of its clients
(GlaxoSmithKline, 2015). Its net income of more than $ 8 billion and an operating income of
more than $ 10 billion makes it one of the largest corporations globally. The massive income
has enabled the company to support some of its charitable events such as the free supply of
drugs and grants to some needy countries and particularly in Africa to support the
management of some deadly diseases such as HIV/AIDS (Rashmi, 2017). Some of its
products are unmatched in both quality and demand. Its consumer products, for example,
Sensodyne and Aquafresh, are among the most selling and longest existing in the industry
GLAXOSMITHKLINE
4
(GlaxoSmithKline. & American Dental Association, 2007). The company’s financial might
has enabled it to operate uninterruptedly despite experiencing some instances that cost it
massive funds. Surprisingly, the company was not shaken by the $ 3 billion penalties that it
received from the US government in a recent civil suit involving its products (Gibson, N.D).
Moreover, not many companies would survive such a huge fine leave alone maintaining their
operations seamlessly. Due to its large number of facilities and products, coupled with its
ability to develop new products, the company has in the recent past sold a number of its
products while buying other companies’ facilities to add to its existing ones. In 2011, for
example, it shed off 17 brands to Prestige Brands at the cost of $ 660 million (Mehmood,
2012). It has managed to take over other companies amounting to billions of shillings such as
Human Genome Sciences in 2013 in a deal worth $ 3 billion. In the recent past, the company
has also engaged in expansion of its facilities with the creation of new manufacturing units
and facilities. Notably, it was able to allocate at least 500 million pounds for the construction
of manufacturing facilities in England and a further $ 1 billion to raise its stake in its Indian
subsidiary in a move to have more control and consequently increase its operational facilities
(GSK, 2015).
GLAXOSMITHKLINE
5
References
Gibson, Liza. (n.d.). GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ
Publishing Group Ltd.
GlaxoSmithKline Pharmaceuticals Ltd. (India). (February 26, 2015). GlaxoSmithKline
Pharmaceuticals Ltd. (India) - Annual Report - December 31, 2014. Reportal.
GlaxoSmithKline. & American Dental Association. (2007). OralLongevity. Chicago, IL:
American Dental Association.
Holzweber, Markus, Holzweber, Markus, Lawson, Virginie, & Addison, Adelaide.
(n.d.). GlaxoSmithKline: the shifting from Patented to Generic Drugs.
Karus, Kärt. (2015). Definition of Relevant Product Market in Reference to R&D Poles in
Pharmaceutical Sector Mergers. Lunds universitet/Juridiska institutionen.
Mehmood, Faisal. (2012). Growth by Merger - A long-term analysis of GlaxoSmithKline.
Rashmi, R. (January 01, 2017). Corporate Social Responsibility of Pharmaceutical Industry
towards Access to Medicine: A Case Study of GlaxoSmithKline.
GlaxoSmithKline Ltd. (2016). GKS Annual report 2015. Available from
http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report/
1
GlaxoSmithKline Weaknesses
GlaxoSmithKline Ltd Weaknesses
Names:
Institution:
GlaxoSmithKline Weaknesses
2
GlaxoSmithKline Ltd Weaknesses
GlaxoSmithKline (GSK) is a company that has been in operation for a long time. It
ranks among the leading pharmaceuticals both in company value and the products that it
manufactures. Its large size, many subsidiaries, and a number of conglomerates give it an
upper hand in the industry. Additionally, the company can afford advanced researches on
various items even when the process of achieving the desirable results gets prolonged. As
with every other company, GSK has its strengths and weaknesses. Despite these weaknesses
having little effect on the operation and performance of the company, these weaknesses create
a significant setback to the jurisdiction where the company operates. The following section
will analyze some of the major weaknesses of GKS, taking both an internal as well as an
external perspective.
Content, labeling, and advertisements of GKS brands
GKS has a very wide variety of brands which range from pharmaceuticals to lifestyle
products. Within the market, most of these products are undisputable and tend to have little
competition. However, the company has in the past faced a number of issues that created
conflict with both the authorities as well as the general public. Ribena, which is one of the
earliest products of the company, is one of such products. Initially, the product was labeled to
create a clinical aspect with inscriptions "widely used in hospitals and clinics" (Wetherington,
Pfister, Banfield, Stone, Krishna, Allerheiligen & Grasela, 2009). However, this created an
issue due to widespread concern over its contents. The product was highly criticized over the
lack of medical value, a factor that hugely discredited its fame among the public. During the
world war, this drink was often served to children as a source of the vitamin. However, the
early 2000s issue regarding the drink led to widespread criticism after it was realized that its
sugar contents were exceeding the threshold for major hospital use (Norman, 2002). Notably,
GlaxoSmithKline Weaknesses
3
it is recommended that sick people, as well as children, consume majorly low-sugar but highenergy products for the purposes of maintaining or restoring their health. Despite the attempts
by the company to give it a health reputation, this reputation was hugely affected when the
concerns were raised. It is now yet known whether this issue played a part in the sale of
Ribena brand by the company in 2013.
Another major branding and advertising issue that brought devastating impacts to the
company was the 2010 collision with the US authorities in 2010. In this case, GKS was fined
a whopping $3.1 billion which, surprisingly, is the highest fine ever imposed on a company in
the pharmaceutical industry by the US judiciary (Gibson, N.D). In this case, the company was
charged under the False Claims Act. Just like the issues raised in the case of Ribena, there
were concerns over adulterated drinks in the early 2000s by the company which instigated the
Federal Drug Agency (FDA) to visit the company and directed the rectification of the issue.
However, the issue was never rectified. Many of the disputed drugs were in those involved in
the treatment of skin problems as well as diabetes. The frequent complaints made it escalate
to high levels that created issues with the authority. After a dispute was filed, the company
was forced to close down the Puerto Rico factory in the year 2009 (Wetherington, Pfister,
Banfield, Stone, Krishna, Allerheiligen & Grasela, 2009). Unfortunately, the case proceeded
until 2010 when the fine was imposed.
Patent disputes over the brands
Due to the nature of the products that the company manufactures, most of them are
covered by patents. These patents are meant to protect the works of the company which
majorly arise after years of lengthy research. The company has the one of most advanced
R&D program globally and invests a lot of funds to research the drugs before manufacturing
sets in (GlaxoSmithKline, 2015). In order to protect the business and guarantee a monopoly
GlaxoSmithKline Weaknesses
4
and total control over the product, the company as well as other competitors secure the right
to the products. Over the past, the company has been engaged in a number of patents that have
a huge effect on its operations (Holzweber, Holzweber, Lawson & Addison, N.D). In one
instance, the company was involved in a number of antitrust cases with the US government
over that led to revoking of some patents due to the discredit that arose as a result of irregular
filing and documentation. At one time, the company was charged over a number of
conspiracies and irregularities in exercising its rights and had its license revoked, and the
patent declared invalid (BMJ, 2009). In the past, the company practiced cross-licensing on its
patents that allowed the large companies to trade in its products while eliminating small
companies. This meant that most of these drugs could only be traded on a large scale. This led
to detrimental effects on its sales since it limited the availability and distribution of the
product. The company has also faced a number of other fines including a 37 million pounds
early this year over irregular price manipulation and unfair competition strategies in the UK
(BMJ, 2009). Its officials have also been involved in a number of briberies that led to a
number of case suits, especially in the UK and Italy.
The above-mentioned issues have led to a discrediting effect on the image of the
company and significantly affected its sales. However, the company has been striving to
adjust to the situation by initiating various corrective measures.
5
GlaxoSmithKline Weaknesses
References
Gibson, Liza. (n.d.). GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ
Publishing Group Ltd.
GlaxoSmithKline Pharmaceuticals Ltd. (India). (February 26, 2015). GlaxoSmithKline
Pharmaceuticals Ltd. (India) - Annual Report - December 31, 2014. Reportal.
Holzweber, Markus, Holzweber, Markus, Lawson, Virginie, & Addison, Adelaide.
(n.d.). GlaxoSmithKline: the shifting from Patented to Generic Drugs
Norman, P. (January 01, 2002). GlaxoSmithKline plc: analysis of patenting 1998 2001. 12, 9, 1407-1415.
Weak Swiss law allows tobacco sponsorship of tennis tournament to go ahead . Putin attacks
firms for paying doctors to prescribe their drugs . GlaxoSmithKline is told to pay
family $2.5m after jury finds paroxetine caused son's heart defects. (October 26,
2009). Bmj : British Medical Journal, 88, 7727, 942.
Wetherington, J. D., Pfister, M., Banfield, C., Stone, J. A., Krishna, R., Allerheiligen, S., &
Grasela, D. M. (September 01, 2010). Model-Based Drug Development: Strengths,
Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in
Drug Development. The Journal of Clinical Pharmacology, 50.
Running head: SWOT ANALYSIS
1
SWOT Analysis
Name
Institutional Analysis
2
SWOT ANALYSIS
SWOT Analysis
The organization GlaxoSmithKline was formed in 2001, and this was because of the
merger between the two companies SmithKline Beecham and Glaxo Wellcome, which were two
major pharmaceutical companies. The organization deals with pharmaceuticals, consumer health
products, and vaccines. The organization has its headquarters in the UK and has branches in over
100 countries globally. The mission statement of the organization is to help people do more, feel
better, and live longer(Ferdous,2015). The organization looks to increase growth, reduce risk,
and improve its long-term financial performance. It aims to do this through growing a balanced
global business, delivering more products of value, and simplifying the operating model of
business. The company looks to create a balanced business portfolio and deliver sustainable sales
with the aim of corporate growth. It also looks to deliver more products of value through a
variety of products.
The company also looks to change how it operates to reduce complexity and increase
efficiency. It functions through responsible business aimed at delivering success and ensuring
that its values are part of its culture. The organization is listed on the New York Stock Exchange
and continues to face stiff competition especially from companies such as Pfizer and
Sanofi.Using a SWOT analysis, it will be possible to further analyze the strengths and
weaknesses of the organization(Ferdous,2015). The organization has continually benefitted from
the vast resources and funds available which have enabled it to employ a strong sales and
marketing unit. The company has embarked on a vigorous marketing campaign that has been
undertaken by its marketing and public relations departments. The organization is the biggest
investor in research and development in the pharmaceutical field in the UK.
3
SWOT ANALYSIS
It continues to provide utilization and manufacturing in the field of chemistry as well.
The organization has over 90000 employees who specialize on exploring new markets. However,
there are a number of shortcomings that the organization continues to face in the line of
operations. One of these weaknesses is the fact that the increased productivity often leads to
increased cases of expired bulk products. Furthermore, there are increasing issues of safety of
some of the drugs that the organization produces, and this has hampered
sales(Ferdous,2015).Due to mass production, the organization has also repeatedly called back a
number of its products due to quality and quantity issues. It has dented the image of the
organization and has stained its record and reputation. The organization also has managed to
identify a number of opportunities in the market. It has singled out the opportunity present in the
oncology market as well as biologics. It has also managed to realize the opportunity to facilitate
potential mergers due to its stable cash flow position.
Through its mergers with other pharmaceutical organizations, it has developed state of
the art laboratories that have enabled the amassment of more funds through profit. The company
has also capitalized on opportunities to expand into new markets through successfully expanding
its operations as well as client base (Ferdous, 2015). However with these opportunities also come
a number of threats to the effectiveness of the organization. One major threat is the high number
of unsuccessful new products due to lack of customer awareness concerning these products.
Another major threat to operations for the organization is the fact that there are increasing
environmental regulation which has become stricter. The fluctuation of the global economy is
another major issue that continues to affect operations of the company. Economic instability
throughout the world has slowed down sales and reduced the market effectiveness of the
company.
4
SWOT ANALYSIS
Another major issue that has a reasonable impact on the company is the threat of
conventional forms of medicine in recent times. Herbal medicine continues to be accepted
recently, and this has affected the operations of the company and reduced sales of its products.
Furthermore, these products have fewer side effects and on many occasions have proven to be
more effective (Ferdous, 2015).Leadership wrangles within the organization are another major
issue of concern within the company. It has led to internal instability and slowed down operation.
However, the company maintains a stable position in the pharmaceutical market and is a
renowned global brand. It continues to rake in huge annual profits and attract more clients as
well as investors. The company does not have much concern about the threat of new competitors
in the market.
The reason for this is because the cost of entering the pharmaceutical industry is very
high and many potential entrants are usually discouraged by this. Another point to note is that
local governments usually impose strict measures to organizations wishing to enter the
pharmaceutical industry (Ferdous, 2015).However, the increasing occurrence of generic
medication in the market has become an issue of concern and has reduced sales of the company
products significantly. These substitutes offer similar products but use different brand names and
offer cheaper pricing for the products. However, despite such occurrences, the brand continues to
embark on an effective marketing strategy that has seen it maintain itself as the preferred global
pharmaceutical brand.
5
SWOT ANALYSIS
References
Ferdous, Z. (2015). Performance analysis of GlaxoSmithKline Bangladesh Limited
Islam, K., & BA, C. C. Critical Analysis of GSK's (GlaxoSmithKline) Business Strategy:
Opportunities, Limitations and Recommendations to achieve Sustainability.
Purchase answer to see full
attachment